
Head-to-Head Comparisons on B/F/TAF Compared With Other HIV Regimens
Sorana Segal-Maurer, MD, reviews research evaluating the efficacy of B/F/TAF compared with other HIV treatment regimens, including dolutegravir plus tenofovir/FTC.
Episodes in this series

BIC = bictegravir
DRV = darunavir
DTG = dolutegravir
F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide
F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate
B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)
DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)
D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)
CAB = Cabotegravir
CAB + RPV = Cabotegravir + Rilpivirine
Video content above is prompted by the following question(s):
- Studies have run head-to-head comparisons on the efficacy of B/F/TAF compared to other regimens, like dolutegravir + tenofovir/FTC, stressing patient adherence and the outcomes associated.
- What are the notable differences in efficacy were seen in these studies?


























